CD38 and neoplasm: Another research team, by combining L82 pulse DC vaccination with anti-CD38 antibody treatment, effectively suppressed tumor growth through a mechanism that relies on the reduction in regulatory T cells in tumors, thereby stimulating anti-tumor immunity in a mouse lung cancer cell line LLC1 that is resistant to immune checkpoint therapy [113].